Get started
Author

Nick Manamley

Observed names: N Manamley, N. Manamley
ORCID: 0009-0003-9325-0323
Observed ORCID: 0009-0003-9325-0323
OpenAlex ID: A5058296074
AMG 151 ( ARRY‐403 ), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes
2015 · L. Katz, N. Manamley, et al. · Diabetes Obesity and Metabolism · 43
Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
2015 · Franz Schaefer, Bernd Hoppe, et al. · Pediatric Nephrology · 31
PDF
Data sharing and the evolving role of statisticians
2016 · Nick Manamley, Steve Mallett, et al. · BMC Medical Research Methodology · 28
PDF
Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
2013 · Peter Choi, Mourad Farouk, et al. · Advances in Therapy · 27
PDF
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
2013 · E. Zitt, D. Fouque, et al. · Clinical Kidney Journal · 25
PDF
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
2024 · Patrick M. Honoré, Massimo Girardis, et al. · Critical Care · 24
PDF
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials
2024 · Patrick M. Honoré, Matteo Bassetti, et al. · Critical Care · 15
PDF
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin
2024 · Alex Soriano, Jeffrey B. Locke, et al. · Clinical Microbiology and Infection · 11
PDF
Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma
2024 · Owen A. O’Connor, Bor-Sheng Ko, et al. · Blood Advances · 10
PDF
Treatment Outcomes Among Patients With a PositiveCandidaCulture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
2024 · Alex Soriano, Patrick M Honore, et al. · Clinical Infectious Diseases · 9
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis
2014 · Simon D Roger, Elena Kolmakova, et al. · Nephrology · 8
Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
2014 · Jan Donck, Lourdes Gonzalez-Tabares, et al. · Advances in Therapy · 7
PDF
EE333 Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK
2023 · N. Muszbek, A. Angdembe, et al. · Value in Health · 5
Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
2013 · M G Vervloet, P W G du Buf-Vereijken, et al. · PubMed · 5
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial
2024 · Anna Sureda, Antonio Pinto, et al. · Hematological Oncology · 3
A phase II study of tinostamustine in patients (pts) with advanced solid tumours.
2023 · Anna Tinker, James Fredric Strauss, et al. · Journal of Clinical Oncology · 3
Paediatric Nephrology
2014 · D. Mekahli, K. Van Straelen, et al. · Nephrology Dialysis Transplantation · 3
Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
2016 · Jan-Christoph Galle, Janet Addison, et al. · Nephrology Dialysis Transplantation · 2
PDF
Cost‐Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom
2026 · Noemi Muszbek, Alisha Angdembe, et al. · Mycoses · 1
PDF
CO89 Integrated Analysis of Efficacy and ICU Length of Stay Data From Phase 2 and Phase 3 Trials of Rezafungin for the Treatment of Invasive Candidiasis and/or Candidemia
2022 · I Bielicka, S Dickerson, et al. · Value in Health · 1
THU-272 The pharmacokinetic profile of a new trientine tetrahydrochloride formulation supports simpler once-daily dosing for the treatment of wilson disease: results of the triumph-3 study
2026 · Karl Heinz Weiss, Thomas Ashdown, et al. · Journal of Hepatology
LBP-038 A novel trientine tetrahydrochloride formulation administered once-a-day for people living with Wilson disease: results from a phase 2 study
2026 · Emmanouil Tsochatzis, Andrew Holt, et al. · Journal of Hepatology
THU-298 Non-ceruloplasmin bound copper measured by speciation assay: response to therapy over 12 months in real world setting of newly diagnosed Wilson disease patients
2026 · Michael Schilsky, Amanda Cheung, et al. · Journal of Hepatology
THU-291 Non-ceruloplasmin bound copper measured by speciation assay: prospective evaluation over 12 months in real world setting of unstable Wilson disease patients
2026 · Michael Schilsky, Amanda Cheung, et al. · Journal of Hepatology
Author response for "Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial"
2024 · Anna Sureda, Antonio Pinto, et al. · Publons reviews and discussion
Works count: 37
Citation count: 261
H-index: 9
I10-index: 9
Year
Topic
Type